Verastem Oncology to Participate in Upcoming September Investor Conferences

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences:

• Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET
• H.C. Wainwright Annual Global Investment Conference in New York City: September 14, 12:00-12:30 pm ET

A live webcast of the fireside chats can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260902001050/en/

For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
[email protected] or
[email protected]

Source: Verastem Oncology

You May Also Be Interested In

• Gradiant Secures Major Water Contract for Hyperscaler AI Data Center Campus in West Texas
• Perfect Stones Publishes 2026 Granite Countertop Installation Guide for Charleston-Area Homeowners
• IBM Ventures Invests in BQP as Quantum-Algorithm Physics Acceleration Reaches Production